The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
32
Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
Lakeland Regional Healthcare
Saint Joseph, Michigan, United States
Abdominal Pain
change in abdominal pain on 0 (no pain) through 10 (worse possible pain) on a visual analog scale
Time frame: 2 hours
Nausea
change in nausea on 0 (none) through 10 (worse possible nausea) on a scale
Time frame: 2 hours
Abdominal Pain
change in abdominal pain on 0 (no pain) through 10 (worse possible pain) on a visual analog scale
Time frame: 24 hours
Nausea
change in nausea on 0 (none) through 10 (worse possible nausea) on a scale
Time frame: 24 hours
Abdominal Pain
change in abdominal pain on 0 (no pain) through 10 (worse possible pain) on a visual analog scale
Time frame: 48 hours
Nausea
change in nausea on 0 (none) through 10 (worse possible nausea) on a scale
Time frame: 48 hours
Treatment Success
both abdominal pain and nausea scores under 2 (none or minimal)
Time frame: 2 hours
Treatment Success
both abdominal pain and nausea scores under 2 (none or minimal)
Time frame: 24 hours
Treatment Success
both abdominal pain and nausea scores under 2 (none or minimal)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 48 hours